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Myelopoiesis is a dynamic process regulated by stimulatory and inhibitory feedback 
mechanisms. Aberrations  in  these regulatory interactions have been  detected with 
cells from patients with leukemia, lymphoma, and myeloproliferative and myelodys- 
plastic disorders (1). We have described in vitro and in vivo cellular interactions that 
may constitute the basis for the suppression of normal hematopoiesis occurring during 
leukemia, and that may be involved in the progression of the disease (1-7). 
A  synthesis  (S)-phase  specific inhibitory activity against  normal  colony-forming 
unit granulocyte-macrophages (CFU-GM)1 is produced by bone marrow, spleen, and 
blood cells from patients with acute and chronic myeloid and lymphoid leukemia, 
lymphoma, and  "preleukemia"  (2,  3,  5).  This  activity was  not  detected  in  bone 
marrow and blood cells of normal donors and had been termed leukemia-associated 
inhibitory activity (LIA;  1-6).  LIA derives from ceils characterized as non-T, non-B 
lymphoidlike cells, or promonocytes, with Fc receptors (2, 5). Greater concentrations 
of LIA are  found  during acute  leukemia  (newly diagnosed  and  untreated,  or on 
therapy but not in remission) than during chronic leukemia (2, 3). Remission of acute 
leukemia is associated with low levels of LIA (3, 6). An LIA-like substance has also 
been detected in bone marrow, spleen, and thymus cells from BALB/c mice infected 
with Abelson virus (7)  and in mice infected with Friend virus (8; and L. Lu and H. 
E. Broxmeyer, unpublished observations). In contrast to its action on normal CFU- 
GM, LIA is not effective in suppressing the growth of CFU-GM from many patients 
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with leukemia and from BALB/c mice infected with Abelson virus and mice infected 
with  Friend  virus  (1-8;  and  unpublished  observations).  LIA  may  thus  confer  a 
proliferative advantage to abnormally responsive progenitor cells. 
We have been interested recently in the association of iron-binding proteins with 
cells  of the  myeloid  and  lymphoid  systems  (9-12)  and  have  described  a  role  for 
lactoferrin in the regulation of myelopoiesis (9,  10). We have noted now that LIA is 
similar in many respects to a subclass of ferritins that are also iron-binding proteins. 
LIA and ferritin  are glycoproteins with high molecular weights (13-15)  and similar 
isoelectric  focus  points  (13,  16,  17). Both  are  elevated  during  acute  and  chronic 
leukemia and decreased during the remission of acute leukemia  (16-18).  Ferritin  is 
considered the main storage protein  for iron in  mammalian cells  and  is thought to 
play a  role in iron metabolism  (14,  15). Ferritin  can be separated  into isoforms (16, 
17, 19, 20), and there is evidence that isoferritins are composed of two types of subunits 
differing  in  charge  and  size  (15-17,  19-22).  The  H  subunit  has  an  approximate 
molecular weight of 21,000 and is high in ferritin associated with heart tissue, and the 
L  subunit  has  an  approximate  molecular weight  of 19,000  and  is  high  in  ferritin 
associated  with  liver  tissue.  The  acidic  isoferritins  are  considered  to  be  composed 
mainly  of H  subunits,  and  the  most  basic  isoferritins  appear  to  be  composed of 
homopolymers of L subunits. The possible association of acidic isoferritins with tumor 
cells and their value in the prognosis and diagnosis of cancer have been the subject of 
conflicting reports  (16,  17,  19,  23,  24).  However, relatively little  evidence has been 
presented that suggests that ferritin may have a role other than as a storage molecule 
for iron (25-27). Iron-depleted ferritin has been noted in human blood leukocytes and 
serum from normal donors and patients with leukemia (28);  in this paper, we identify 
LIA as acidic isoferritins that do not appear to require iron for their activity. Evidence 
is given for the role of acidic isoferritins as normal inhibitory regulators of myelopoiesis, 
a  role  that  is  distinct  from  that  of lactoferrin.  This  is,  we  believe,  the  first  clear 
demonstration that the acidic and basic isoferritins can be distinguished in terms of 
biological function. 
Materials and Methods 
Source of LIA.  LIA was isolated from more than 5,000 samples of extracts of nucleated bone 
marrow,  spleen, and blood cells collected over a  5-yr period  from  more than  1,000 different 
patients  (Memorial  Hospital,  New  York) with  acute  and  chronic  leukemia,  as  described 
previously (13). 
Source of Ferritin.  Ferritin was isolated from human spleen, liver, heart, and placental  tissue. 
Spleen tissue was obtained from normal individuals  undergoing either emergency splenectomy 
for a  punctured spleen  (Brooklyn Jewish Hospital,  New York), from  fatally  injured  persons 
whose kidneys were to be used  for transplantation  purposes  (University  of Heidelberg,  Ger- 
many), from a patient with chronic myelogenous leukemia undergoing splenectomy as part of 
the treatment  protocol  (Memorial  Hospital,  New York), and  from  patients  with  Hodgkin's 
disease after staging laparotomy (St~idtische Krankenanstalten,  Darmstadt, Germany).  Normal 
human heart and liver tissues were obtained post mortem from the University  of Heidelberg, 
Germany, and normal human placenta ferritin was a gift from Dr. Bohn, Behringwerke A. G. 
Marburg, Germany. Ferritin  was isolated from the above tissues immediately  upon arrival  or 
after storing the tissues at -20°C. 
Isolation of LIA.  Pooled samples of cell extracts were isolated by a sequence of procedures as 
described  previously  (I3).  After  uhracentrifugation,  Sephadex  G-200,  and  carboxymethyl 
cellulose (CMC),  the pooled  active  fractions  from CMC had a specific activity of 6.7 ×  1012 
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gel electrophoresis (SDS-PAGE) or concanavalin A-Sepharose. The samples were applied to 
the  SDS-PAGE gradient  (5-20%)  slab gel,  pH  8.8,  with  3%  stacking gel  (pH  6.8)  without 
heating the sample mixtures. In some experiments, and where noted specifically in the text, the 
sample mixtures were heated at  100°C for  10 min to reduce the samples. Molecular markers 
included horse ferritin (500,000 mol wt; Sigma Chemical Co., St. Louis, Mo.), phosphorylase 
b  (94,000 mol wt), human milk lactoferrin (76,000 mol wt; Metallo Protein Laboratories, Ltd, 
Windsor, Canada),  bovine serum  albumin (68,000  mol  wt),  ovalbumin (43,000  mol  wt), 
carbonic anhydrase (29,000  mol wt), trypsin inhibitor (20,100  mol wt), hemoglobin (16,000 
mol wt) and a-lactalbumin (14,000 mol wt) from Pharmacia Fine Chemicals Inc., Piscataway, 
N. J. Active fractions from the CMC column or from SDS-PAGE were analyzed by analytical 
(thin-layer) or preparative isoelectric  focusing (IEF). 
Isolation  of Ferritin.  Ferritin was isolated at Sloan-Kettering Institute, New York,  or at the 
University of Heidelberg, Germany. The tissue was cut into small pieces and, in the case of 
macroscopically involved  spleens from patients with Hodgkin's disease, the nodes were separated 
and the nodal and non-nodal tissues were isolated. The tissues were homogenized in a Waring 
blender  (Waring Products  Div.,  New  Hartford,  Conn.)  with  a  volume of distilled  water 
equivalent to twofold the weight of the tissue,  brought to 75°C for  15 min, and then cooled 
rapidly in an ice bath. Coagulated protein was removed by filtration or by centrifugation at 
2,500 g for 20 min. The pH of the filtrate was adjusted to 4.6 and the supernate was adjusted 
to  pH  5.5  after  centrifugation. The  filtrate was  placed  in  an  ice  bath  for  1 h  and  then 
centrifuged at  12,000 g for 20 min. In both cases, the filtrate and supernate were then brought 
to pH 6.5 with 0.2  M/1  liter KzPO4;  (NH4)SOz  was added to half saturation. After 48 h  at 
4°C, the insoluble  fraction from the filtrate was collected by centrifugation  and dialyzed against 
glass-distilled water (4 ×  2 liter vol)  (29, 30). Ferritin isolated from the spleen of one patient 
with chronic myelogenous leukemia and one normal donor were then isolated by Sephadex G- 
200,  CMC,  SDS-PAGE, analytical and preparative IEF, and concanavalin A-Sepharose as 
described for the isolation of LIA. In one experiment, the insoluble fraction after half saturation 
with  (NH4)SO4  from  a  portion  of  a  sample  from  the  spleen  of  a  patient  with  chronic 
myelogenous leukemia (CML) was redissolved in a solution containing 5 g of 3 CdSO4.8H20/ 
100 ml. This was left at 4°C for 48 h and the resulting crystals were collected by centrifugation 
at 2,500 g and dialyzed before further isolation by Sephadex G-200 and CMC. Other sources 
of ferritin (heart, N --- 4; Hodgkin's spleen, N =  8; normal spleen, N =  3; normal liver, N -- 3) 
were  subjected  to  column chromatography on  Sepharose  6B  (Pharmacia  Fine Chemicals, 
Uppsala, Sweden) after half saturation with (NH4)SO4. Optical density was measured at 280 
nM and the peak fractions were concentrated with a UM 10 filter (Amicon Corp., Dusseldorf, 
Germany). The normal heart, Hodgkin's spleen, normal spleen, and normal liver ferritin were 
passed through an immunoabsorbent column consisting of Sepharose 4B coupled to human 
serum antibodies previously absorbed with human or liver ferritin, to absorb out contaminating 
proteins. Human placental ferritin was isolated by Dr. Bohn as described previously (31). A 
single sharp precipitation line was found in the peak fractions containing ferritin in double 
immunodiffusion studies in agarose with rabbit anti-human Hodgkin's spleen ferritin serum, 
which  recognizes  both  acidic  and  basic  isoferritins. The  final  preparations  did  not  react 
immunologically with anti-human serum that did not contain antibodies to ferritin. Protein 
concentrations were determined by the ninhydrin method (32) and/or the method of Lowry et 
al. (33). Ferritin iron was checked qualitatively after SDS-PAGE with 2% (wt/vol) potassium 
ferrocyanide in 3% trichloroacetic acid, or quantitatively by atomic absorption spectrophotom- 
etry at 248.8  nm (305B;  Perkin-Elmer Corp., Norwalk, Conn.) and the purity of ferritin was 
confirmed by gel diffusion and radioimmunoassay as described below. 
Preparation  of Antisera  to  Ferritin.  Rabbits were  immunized with either crude or  purified 
human spleen ferritins. The  first  injection was  given in Freund's complete adjuvant. Each 
rabbit received  1 mg of protein in multiple intramuscular sites  at  intervals of 4  wk over a 
period of up to 12 mo. Blood was collected 7-8 d after each injection and the serum was stored 
at -20°(3. Antisera against human heart ferritin were obtained by immunizing  goats with the 
purified heart ferritin in complete Freund's adjuvant intradermally at multiple sites at 4-wk 
intervals over a  period of 4-6 mo.  Antisera were purified by an immunoabsorbent column 
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immobilized in cyanogen bromide-activated Sepharose 4B. To obtain antisera with a greater 
degree of specificity for either the acidic or basic isoferritins, aliquots of goat anti-human heart 
ferritin or rabbit anti-human Hodgkin's spleen ferritin serum were purified by immunoabsorp- 
tion. Acidic or basic isoferritins prepared by preparative isoelectric  focusing were coupled to 
cyanogen bromide-activated Sepharose 4B beads (34). 
Rabbit anti-HeLa cell  ferritin  (unabsorbed)  (16) was  generously supplied by Dr. J.  W. 
Drysdale (Tufts University School of Medicine, Boston, Mass.).  Antiserum against the H or L 
subunits from  human liver  ferritin  (21,  22)  was  generously supplied by  Dr.  I.  Listowsky 
(Einstein Medical Center,  Bronx, N.  Y.),  and purified rabbit immunoglobulin fractions to 
human spleen ferritin were purchased from Dako Immunoglobulins  Ltd. (Accurate Chemical 
and Scientific Corp., Hicksville, N. Y.). 
Specificity of the antisera was checked by double immunodiffusion in 1.0% agarose gels in 
barbitone buffer, pH 8.6, using human spleen and heart ferritins and LIA as antigens, and by 
radioimmunoassay. 
Radioimmunoassay of Ferritin.  Two assay systems were used. In one assay, the purified ferritin 
was  labeled  and  competed  in  a  two-step  procedure  with  test  material  and  standards  for 
antibody binding sites.  This is referred  to as the labeled antigen assay.  In the other assay, 
purified antibodies to ferritin, isolated as described above, were used in a three-step procedure 
in which the test material and standards were added in the second step and incubated for 24 
h at 4°C; the tubes were washed and the labeled antibodies were added in the third step. This 
is referred to as the labeled antibody assay. 
Iodination.  Purified ferritin and purified ferritin antibodies were trace-labeled with lzsI by 
the chloramine T  method (35). 2 mCi of Na 125I (New England Nuclear, Boston, Mass.)  were 
brought up to  100 #1 in 0.4 M  borate buffer, pH 8.0.  50/~1 of Na[125I] was added to 5 p.g of 
ferritin in a siliconized glass vial. 10/xg chloramine T in 10/xg of borate buffer was added to the 
vials and gently agitated for  15 s.  The reaction was terminated by adding 15 #1 of sodium 
metabisulfite in  15  #1  of borate  buffer.  A  Sephadex  G-200  column  (0.5  ×  0.5  cm)  was 
equilibrated with borate buffer and pretreated  with  bovine serum albumin. Bovine serum 
albumin (25 mg in 500 #1 of buffer) was added as a "carrier," and bound and free msI-ferritin 
was then separated by gel chromatography. 
The immunoreactive fractions were pooled with 0.06 M barbitone buffer, pH 9.6, containing 
250 mg/100 ml bovine serum albumin. The small amount of solution remaining  in the "reaction 
tube" was used to assess the percentage of iodination by the trichloracetic acid precipitation 
method. Immunoreactivity  was assessed by the ability of the iodinated or noniodinated protein 
to bind to the antibody coated vials. 
Antibody Coating of Tubes.  Polypropylene tubes (Walter Sarstedt, Inc., Princeton, N. J.) were 
coated with ferritin antibodies by a  modification of the  method of Catt  and Tregear (36). 
Antibodies were diluted 2  ×  10  -4 in 0.06  M  barbitone buffer, pH  9.6,  as  determined by a 
previous  titration  curve.  Preliminary studies  showed  that  this  dilution gave  85%  of  the 
maximum binding  capacity after 24 h. 1 ml of diluted antibody was added to each vial and the 
vials were left at 4°C for 24 h. The vials were washed three times with 0.9% NaCI, once with 
0.9% NaC1 containing 1 g/100 ml of bovine serum albumin (to saturate nonantibody-coated 
binding sites), and three times with 2 ml of normal saline. The coated tubes were kept at 4°C 
for up to 1 wk. 
Treatments.  All  treatments were  performed  with  the  most  purified preparations of LIA 
containing specific activities of 6.7 ×  10t2-1.0 ×  1014 U/mg protein (13) and with normal and 
CML-spleen ferritin which were isolated by CMC, SDS-PAGE, and IEF. 
Enzymatic Digestion.  The enzymes shown in Table III were purchased from Sigma Chemical 
Co. and were used as described previously (13). 
Periodate Oxidation.  The test sample (100 #1) was added to 2/xl of 0.01 M potassium periodate 
in 0.1  M  sodium acetate. HC1, pH 5.0, and the solution was incubated in the dark for 4 h at 
4°C. The reaction was stopped by the addition of 200 #1 of 50% sucrose per 2 ml of sample. The 
oxidized samples were dialyzed against 2 mM sodium phosphate buffer (pH 7.0). 
Temperature Treatments.  Samples were exposed to 37°C for 5 d, 56°C for 30 rain and 75°C 
for 5-20 min. 
Iron Depletion.  Samples were iron depleted by reduction. 1 mg of ferritin was mixed with a -50 
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FIG.  1.  The  comparative  isolation  of inhibitory  activity  from  LIA  (A),  CML-spleen  ferritin  (B), 
and  normal  spleen  ferritin  (C)  by SDS-PAGE.  Absorbance  is not  shown  but  was detectable  only  in 
gel fraction  1 for both  CML  spleen  and  normal  spleen  ferritin.  Control  colony  and  cluster  numbers 
ranged  from 210 to 450 in  individual  experiments,  k~,  10  ° dilution; R,  10  -1 dilution;  ill, 10  -5 dilution. 
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F1o. 2.  The comparative migration of protein bands from LIA and CML-spleen  ferritin  after 
reduction (A-C) and under nonreducing  conditions  (D, E, and F) after SDS-PAGE. The numbers 
signify the approximate molecular weights of the markers. A, reduced CML-spleen isoferritin (pH, 
4.7); B, reduced CML-spleen acidic isoferritin (pH, 5.8); C, reduced LIA; D, LIA (CMC); E, LIA 
(pH, 4.7); F, CML-spleen acidic isoferritin (pH, 4.7). 
200-#M solution of reduced flavin mononucleotide plus sodium dithionite (2.0 mM) in 25 mM 
Tris. HC1, pH 7.4. This was further reduced by dialysis against 10 mM thioglycolytic  acid (37). 
The  samples  were  then  dialyzed  against  glass  distilled water  (5  ×  2  liter  vol)  and  iron 
measurements were made by atomic absorption spectrophotometry. 
Reducing Conditions of Subunit Dissociation.  Samples were mixed with 10% 2-mercaptoethanol 
in 0.125 M  Tris buffer, pH 6.8, boiled for 10 min, and dialyzed against glass-distilled  water (5 
X 2 liter vol; 38). 
Assay  for LIA.  Colony (>50 cells/aggregate) and cluster (3-50 cells/aggregate) formation of 
bone marrow cells was stimulated by exogenously supplied colony stimulatory factors (CSF) as 
described previously (13).  Plates were scored after 7 d  of incubation, a  time we have shown 
previously to be optimal for demonstration of inhibition of CFU from normal donors by LIA 
(2).  To ensure  that  the  scorer was  unaware  of the  nature of the samples to  be assessed for 
inhibitory activity, the samples were coded in >70% of the studies by another person before 
being assayed. All the antisera inactivation studies and at least two complete experiments in 
each category were scored in this way. 
Statistical Analysis.  3-5 plates were scored for each sample and the probability of significant 
differences between samples was determined by use of Student's t test. 
Results 
Comparative Biochemical Isolations of LIA and Ferritin.  To substantiate the biochemical 
similarities between  LIA  and  ferritin  (13-17),  the  samples  were  isolated  by  SDS- 
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a combination of procedures, including Sephadex G-200 and CMC, and had a specific 
activity of 6.7 ×  1012 U/mg protein (13). Highly purified samples of ferritin obtained 
from spleen tissue of a  normal accident victim and from a  patient with CML were 
also used. The samples were isolated by nonreducing SDS-PAGE. Two preliminary 
experiments using gel cuts (20 mm each) localized the inhibitory activity of the three 
samples  in  the  region  of apparent  molecular weights  of >300,000.  A  subsequent 
experiment  using  gel  cuts  of  10  mm  each  localized  the  inhibitory activity  in  an 
apparent molecular weight region >450,000. The graph shown in Fig.  1 demonstrates 
the average results of four experiments for LIA, three for CML-spleen ferritin, and 
four for normal spleen ferritin, in which 5-mm gel cuts were made in the molecular 
weight  region of 300,000-550,000.  From these  experiments an  apparent  molecular 
weight range of ~450,000-550,000 (gel fractions 1 and 2) was calculated for the three 
samples with most of the inhibitory activity localizing in the range of 550,000 (gel 
fraction  1). All significant activity was lost from gel fraction 2 after a  10  -1 dilution, 
but plateau levels of inhibition were still present in gel fraction 1 after a  10  -5 dilution 
(P <  0.001). No significant activity was noted in the region of the stacking gel (lst  15 
mm,  gel  slices 0).  Fig.  2  demonstrates  the  nonreduced  protein  bands  of LIA  (D, 
previously isolated to the stage of CMC, and E, pH 4.7 after IEF) and acidic isoferritin 
(pH  4.7)  isolated  from the spleen of a  patient  with  CML.  The three preparations 
comigrated with the horse spleen ferritin molecular weight marker (~550,000 mol wt) 
and inhibitory activity (50-55%, P  <  0.001) was detected only in this region of the 
gel.  Reduction of the acidic LIA  (Fig.  2C)  and acidic spleen ferritin  (Fig.  2 B)  by 
heating the sample mixture for 10 min at  100°C before running the samples on the 
gel resulted in two bands of protein detected in the molecular weight range of 20,000. 
For comparison, a preparation of basic isoferritin (pH 5.8) was reduced (Fig. 2 A) and 
one band of protein coincident with the lower molecular weight  band of the other 
two reduced preparations was  seen  (Fig.  2 A).  Inhibitory activity was  not  detected 
after reduction in the region of the low molecular weight bands (Fig. 2 A-C). 
A profile of inhibitory activity after IEF of three samples is shown in Fig. 3. This 
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FiG. 3.  The comparative isolation of inhibitory activity from LIA (O), CML-spleen ferritin ([-1), 
and normal spleen ferritin (A) by analytical and preparative IEF. Absorbance  is not shown but was 
detectable in the ranges of pH 4.4 to 5.9. Control colony and cluster numbers ranged from 150 to 
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includes the average of four experiments for LIA, five experiments for CML-spleen 
ferritin, and two experiments for normal spleen ferritin; the results of analytical and 
preparative IEF that were similar are combined. Maximum activity was detected at 
pH 4.7 (P <  0.001)  with significant activity also noted at pH 4.6 (P <  0.01), pH 4.8 
(P <  0.001), and pH 4.9  (P <  0.01).  Low but significant activity was noted for the 
CML-spleen ferritin at pH 4.5 (P <  0.05).  Bands of protein from samples of LIA (pH, 
<5.0, which was first isolated by preparative IEF) and ferritin from the spleen of a 
patient with CML were seen after IEF in polyacrylamide gels  (Fig. 4).  Bands were 
noted in the LIA sample at pH 4.5, 4.65,  4.94, and 4.97, and in the spleen sample at 
pH 4.5, 4.65, 4.94, 4.97, and 5.65. Inhibitory activity in both samples was localized to 
the pH ranges of 4.65-4.97  with optimal inhibitory activity in the range of pH 4.65 
(50-55%, P <  0.001). 
Detection of Ferritin in Samples of LIA by Gel Diffusion.  Samples of LIA (pH <5.0), 
acidic  (pH  4.9),  and basic  (pH  5.8),  heart  ferritin isolated by preparative IEF and 
Hodgkin's spleen  ferritin  (containing acidic  and basic  ferritins)  were analyzed for 
immunological cross-reactivity with anti-H and -L subunit sera (32, 33), rabbit anti- 
Hodgkin's spleen ferritin, and goat anti-human heart ferritin sera by the Ouchterlony 
diffusion  technique  (Fig.  5).  The  latter  two  sera  were  used  unabsorbed  or  after 
absorption  with  basic  heart  ferritin  (pH  5.8).  Strong precipitation  lines were seen 
between LIA, acidic heart ferritin (F 3), Hodgkin's spleen ferritin (F 1), and the anti- 
H  subunit sera, and the unabsorbed and absorbed rabbit and goat anti-ferritin sera 
(Fig. 5 a-c, e, and f). Very faint precipitation lines were noted between LIA, acidic 
heart  ferritin,  and  anti-L subunit  antiserum  (Figure  5d).  Basic heart  ferritin was 
recognized  strongly  by  anti-L  subunit  antiserum  (Fig.  5d)  and  very  weakly  by 
FIG. 4.  The comparative migration of protein bands from LIA, (pH <5.0) and CML-spleen 
ferritin. The pl values  are 4.5 (a), 4.65 (b), 4.94 (c), 4.97 (d), and 5.65 (e). 1434  ACIDIC ISOFERRITINS, REGULATORS OF MYELOPOIESIS 
Fro.  5.  Ouchterlony gel diffusion of LIA and ferritin against anti-ferritin sera. The antigens used 
were LIA (pH 5.0), acidic heart ferritin, pH 4.7 (F3), basic heart ferritin, pH 5.8 (F1), and Hodgkin's 
spleen ferritin (F2). The antisera used were: I, anti-H  subunit sera (a); II, rabbit  anti-Hodgkin's 
spleen ferritin absorbed with basic ferritin (pH 5.8; b); III, goat anti-heart  ferritin absorbed with 
basic ferritin (pH 5.8; c); IV, anti-L subunit sera (d); V, unabsorbed rabbit anti-Hodgkin's spleen 
ferritin (e); and VI, unabsorbed goat anti-heart ferritin (0. 
unabsorbed  goat  anti-heart  ferritin  sera  (Fig.  50.  These  results  demonstrate  the 
presence of acidic isoferritins  in the preparation  of LIA. 
Detection of Ferritin in  Samples of LIA  by  Radioimmunoassay.  Radioimmunological 
detection of ferritin was accomplished using either labeled antigen or labeled antibody 
(Table I). Three different unabsorbed antisera and one absorbed antiserum were used 
to coat the tubes. None of the antisera recognized lactoferrin or transferrin  (data not 
shown). Detection of ferritin by radioimmunoassay has been shown by others to vary 
with the type of antibody used and may underestimate,  especially with regards to the 
acidic  isoferritins,  the actual  content  of ferritin  present  (16).  This  is clearly demon- 
strated  by the data in Table I  using the labeled  antigen assay. In this assay, ferritin 
was detected in all the samples but the rabbit anti-HeLa cell ferritin serum was more 
sensitive  in  recognizing the  ferritin  in  LIA and  the  functionally active CML  spleen 
samples. Moreover~ a comparison of the two assays using unabsorbed goat anti-normal 
heart ferritin and unabsorbed rabbit anti-spleen ferritin demonstrated that the labeled 
antibody technique was more effective in recognizing the acidic isoferritins  than  the 
labeled  antigen  technique.  Very little  difference was noted between  the unabsorbed 
goat anti-normal  heart  ferritin  and this antiserum  absorbed with basic ferritin  using 
the labeled  antibody procedure.  The data in  this table  demonstrate  that  samples of 
LIA (pH 4.7) and CML spleen  (pH 4.7) contain at least 90-95% ferritin. 
Inactivation of the Action of LIA and Ferritin by Anti-Ferritin Sera.  Six  different  anti- 
human  ferritin sera were able to inactivate  the inhibitory action of LIA and ferritin. 
The  antisera  used  included  three  rabbit  anti-Hodgkin's  spleen  ferritins,  two  rabbit 
anti-normal spleen ferritins (one of which was purchased commercially), and one goat 
anti-normal heart ferritin. The samples containing inhibitory activity included crude BROXMEYER, BOGNACKI, DORNER, AND DE SOUSA 
TABLE I 
Determinations of Ferritin Concentrations by Radioimmunoassay 
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Labeled antigen  Labeled antibody 
Goat anti-nor- 
Antisera used to 
Unabsorbed rab-  Unabsorbed goat  Unabsorbed rab-  Unabsorbed goat  real heart ferri-  Unabsorbed rab- 
coat tubes 
bit anti-HeLa  anti-normal  hit anti-spleen  anti-normal  tin absorbed  bit anti-spleen 
cell ferritin  heart  ferritin  ferritin  heart  ferritin  with basic heart  ferritin 
ferritin, pH 5.8 
LIA 
CMC  68  68  24  80  83  72 
SDS-PAGE  85  74  56  90  94  77 
IEF (pH 4.7)  90  71  65  92  94  80 
Ferritin 
CML-spleen (CMC)  94  84  70  87  89  76 
CML-spleen, pH 4.7  95  65  fi5  89  90  73 
CML-spleen, pH 4.9  85  84  70  92  92  75 
CML-spleen, pH 5.3  80  90  85  86  85  86 
CML~spleen, pH 5.5  90  90  92  83  78  89 
CML-spleen, pH 59  97  90  94  81  75  89 
Details  on  radioimmunoassay  are  given  in  Materials  and  Methods.  The  standards  for  all  the  assays  were  CML-spleen  ferritin.  Protein 
determinations were made by the method of Lowry et al (33). 
LIA,  LIA  isolated  by  SDS-PAGE,  LIA  isolated  by  preparative  IEF,  CML-sp|een 
ferritin,  normal  spleen  ferritin,  and  normal  heart  ferritin.  The  specificity of two 
different antisera  for the  acidic  isoferritins is  shown  in  Table II.  Ferritin  antisera, 
previously absorbed with basic isoferritins on a solid-phase immunoabsorbant column 
whose specificity was  demonstrated  in Fig.  5,  were still capable of inactivating the 
inhibitory activity of the  LIA  and  ferritin samples.  However, the  ferritin antisera 
absorbed  with  the  acidic  isoferritins  lost  their  inactivating  capacity.  As  further 
controls, antisera were assessed for their capacity to inactivate a  neutropenia-associ- 
ated inhibitory activity (NAIA), which has been shown to be different from LIA (39). 
The above anti-human ferritin sera inactivated the inhibitory activity of the samples 
of LIA and ferritin but not of NAIA (data not shown). 
Comparative Physicochemical Characteristics of LIA  and Ferritin.  The effect of various 
treatments on the activity of LIA and ferritin is presented in Table III. The action of 
LIA and ferritin were inactivated by treatment with trypsin, chymotrypsin, pronase, 
and  periodate.  The  apparent  glycoprotein  nature  of  the  inhibitory  activities  is 
consistent with the results shown in  Fig.  6.  The inhibitory activity in  the LIA and 
ferritin samples bound to concanavalin A-Sepharose columns and were eluted off by 
ix-methyl mannose. Heating at  100°C under reducing conditions also inactivated the 
samples  (Table  III).  The  effect  of the  latter  treatment  was  confirmed  when  no 
inhibitory activity was  recovered from  the  SDS  polyacrylamide gels  in  which  the 
samples  had  been heated to  100°C  before placing the sample  mixtures on the  gel 
(LIA,  two  experiments;  CML  and  normal-spleen  ferritin,  one  experiment  each). 
Confirmation of the breakdown of the samples into subunits was apparent with the 
LIA and CML-spleen ferritin, which demonstrated two protein bands in the molecular 
weight region of-20,000 (Fig. 2 B and C). LIA and ferritin were not inactivated by 
treatment  with  DNase,  RNase,  neuraminidase,  lipase,  and  phospholipase  C.  The 
activity  of LIA  and  ferritin  was  not  altered  by  treatments  yielding  apparently 
complete iron depletion; an untreated sample of CML-spleen ferritin contained  1.34 
/lg  iron/ml  and  an  untreated  sample  of CML-spleen  acidic  isoferritin  (pH  4.7) 
contained 0.5/~g iron/ml, and no iron could be detected in the iron-depleted samples. 1436  ACIDIC ISOFERRITINS,  REGULATORS OF MYELOPOIESIS 
TABLE  II 
Specificity of the Anti-Ferritin Inactivation of the Inhibitory Activity of Ferritin and LIA 
Antiserum ab-  Colonies and 
Antiserum to ferritin*  sorbed  with~  Test material§  clusters H  %A 
None 
None 
None 
m 
m 
McCoy's medium  230 ±  8  -- 
Spleen ferritin  132 ±  7¶  -43 
LIA-IEF  130 ±  6¶  -43 
Rabbit anti-Hodgkin's spleen 
Rabbit anti-Hodgkin's spleen 
Goat anti-normal heart 
Goat anti-normal heart 
Unabsorbed  Spleen ferritin  237 +  12  +3 
Unabsorbed  LIA-IEF  218 +  5  -5 
Unabsorbed  Spleen ferritin  222 ±  7  -3 
Unabsorbed  LIA-IEF  234 ±  4  +2 
Rabbit anti-Hodgkin's spleen  Basic 
Rabbit anti-Hodgkin's spleen  Basic 
Goat anti-normal heart  Basic 
Goat anti-normal heart  Basic 
Spleen ferritin  220 ±  6  4 
LIA-IEF  230 ±  9  0 
Spleen ferritin  234 ±  10  +2 
LIA-IEF  226 ±  6  -2 
Rabbit anti-Hodgkin's spleen  Acidic 
Rabbit anti-Hodgkin's spleen  Acidic 
Goat anti-normal heart  Acidic 
Goat anti-normal heart  Acidic 
Spleen ferritin  125 + 8¶  -46 
LIA-IEF  135 ±  7¶  -41 
Spleen ferritin  127 ±  5¶  -45 
LIA-IEF  118 ±  3¶  -49 
* One  part  antiserum  (10  -2  dilution)  to  four  parts  test  material  were  incubated  for  1.5  h  at  room 
temperature before the assay. The antiserum (unabsorbed and absorbed)  had no effect on the assay (+3 
to -5 %A from McCoy's medium control). 
:~ Absorption of the antisera is explained in Materials and Methods. Rabbit anti-Hodgkin's spleen ferritin 
was  absorbed with either Hodgkin's spleen  ferritin, pH 5.6  (basic)  or pH 4.9  (acidic),  and  goat anti- 
normal heart ferritin was absorbed with either Hodgkin's spleen ferritin, pH 5.9 (basic) or pH 4.9 (acidic). 
§ Spleen ferritin came from a  patient with CML and contained 94% ferritin as determined by radioim- 
munoassay using rabbit anti-HeLa cell ferritin, and the pooled LIA after IEF (pH 4.7) contained 90% 
ferritin (see Table I). Preincubation with antiserum was done with test material containing 10  -9- t0 -~ M 
ferritin. 
II Data for colonies and clusters  are shown but results for colonies were similar.  Five plates were scored per 
datum point. 
¶ Significant change, P <  0.0025. 
Interestingly,  although  the inhibitory activity of purified samples  of LIA and  ferritin 
was  extremely  heat  stable,  crude  LIA,  which  was  not  dialyzed  or  collected  in  the 
presence  of phenylmethylsulfonylfluoride  (PMSF),  a  serine  protease  inhibitor,  was 
very  sensitive  to  inactivation  by  heat.  This  latter  phenomenon  may  have  resulted 
from  contamination  of the  crude  LIA  preparations  with  proteolytic  enzymes.  It  is 
known  that  PMSF  stabilizes the activity of crude preparations  of LIA against  loss by 
heat treatment  (2)  and stabilizes ferritin molecules (40). 
Titration  of the  Inhibitory  Activities  of LIA  and Ferritin.  LIA  is  S-phase  specific  in 
action  and  when assayed  for its capacity to inhibit  colony- and  cluster-forming cells, 
it exhibits a  titration curve of inhibition that  plateaus between 30 and 60% of control 
values  (3).  A  plateau  curve of inhibition  is noted  in Fig.  7  for all the samples  tested. 
The molarities were calculated from the protein content of the samples as determined 
by the method  of Lowry et al.  (33)  and assumes a  molecular weight of 550,000  for all 
the samples.  The one sample of ferritin isolated by crystalization with CdSO4 resulted 
in ~50% inhibition at  10  -l° M, but was not titrated  for its activity and is not included 
in the titration  curve. CML-spleen  ferritin  (pH 4.7),  LIA (pH 4.7),  and  normal heart 
ferritin contained the more potent activities with plateau levels of inhibition detected BROXMEYER,  BOGNACKI,  DORNER,  AND  DE  SOUSA 
TABLE  III 
Comparative Physicochemical Stabilities of LIA and Ferritin 
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Treatment 
Percentage of change (Y ±  1 SEM) from control 
CML-spleen ferri-  Normal spleen 
LIA* (5):~  tin (3)§  ferritin (2)11 
None  --47 ±  4  --46 ±  3  --54 +  4 
Treatments mactivatmg inhibitory activity 
Trypsin  0 ±  2  +1 +  3  +2 :t:2 
Chymotrypsin  -1 ±  2  -3 ±  3  -2 ±  2 
Pronase  -1 ±  2  -3 ±  2  -1  +  5 
Periodate  -1  ±  1  -1  ±  2  -5  ±  1 
Subunit breakdown  -1 ±  2  -1 :lz 4  N.D. 
Treatment not inactivating inhibitory activity 
DNase  -44 ±  4  -47 ±  3  -51 ±  1 
RNase  -46 ±  4  -45 ±  5  -53 ±  3 
Neuraminidase  -49 ±  5  -46 ±  6  -47 ±  4 
Lipase  -46 ±  4  -46 ±  3  -52 +  2 
Phospholipase C  -46 ±  4  -50 +  3  -53 ±  7 
Iron depletion  -44 ±  4  -46 ±  6¶  N.D. 
37°C (5 d)  -49 ±  4  -42 ±  4  N.D. 
75°C (20 min)  -55 ±  4**  -42 ±  4  N.D. 
* Data include results using LIA isolated by CMC, CMC and then SDS-PAGE, and CMC and then IEF 
(pH 4.7).  LIA isolated after each purification stage was tested at least once with the above treatment 
protocols. The subunit breakdown and iron-depletion experiments were performed on LIA isolated by 
SDS-PAGE or IEF. 
:~ Parentheses indicate the number of different samples subjected to the full treatment protocol.  Each 
different sample population within a column was assayed on a different normal bone marrow. 
§ Data include ferritin isolated by CMC, CMC and then SDS-PAGE, and CMC and then IEF (pH 4.7). 
II Data include ferritin isolated by CMC. 
¶ Treated and untreated samples of ferritin (5.4 mg/ml each) isolated by CMC were assessed  for their 
content of iron by atomic absorption spectrophotometry. Also,  an untreated sample of CML-spleen 
ferritin contained 1.34/zg iron/ml, and an untreated sample of CML-spleen acidic isoferritin (pH 4.7) 
contained 0.5/~g iron/ml, and no iron could be detected in the iron-depleted samples. 
** Crude LIA (dialyzed cell extract, N  -  three experiments) was inactivated after treatment at 75°C for 
5 min but LIA was isolated by CMC, CMC and then SDS-PAGE, or CMC and then IEF (pH 4.7), was 
resistant to treatment with temperatures of 75°C for 20 rain. 
at  10-16-10 -17 M,  and  some significant activity  (P <  0.05)  still was detected  at  10  -18- 
10  -is  M.  CML-spleen  ferritin,  Hodgkin's  spleen  ferritin,  normal  placental  ferritin, 
and  LIA  iso!ated  by  SDS-PAGE  were  nearly  as  potent,  with  plateau  levels  of 
inhibition  noted  at  10-15-10 -16 M  and  significant activity  (P <  0.05)  was still seen at 
concentrations  of  10-17-10 -18  M.  The  effect  of normal  spleen  ferritin  fell  into  two 
categories, in which two samples were slightly less active than  the CML-spleen  ferritin 
and  two  other  samples  were  only active  to  10-1a-10 -14 M.  Normal  liver ferritin was 
active to  10-1g-10 -16 M. 
Comparative Action of LIA and Ferritin on CFU-GM from Patients with Leukemia.  LIA is 
not  active  against  CFU-GM  from  many  patients  with  leukemia  (1,  3,  6).  For  this 
reason,  crude  LIA,  LIA  purified  by  SDS-PAGE,  CML-spleen  ferritin,  CML-spleen 
acidic isoferritin (pH  4.7), and  normal  spleen ferritin at concentrations  of 10  -1°- 10  -la 
M  were assessed  for their capacity  to inhibit colony and  cluster formation  in samples 
of bone  marrow  from  patients  with  leukemia.  The  data  shown  in  Fig.  8  are  divided 1438  ACIDIC  ISOFERRITINS,  REGULATORS  OF  MYELOPOIESIS 
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FIG.  6.  The comparative isolation of inhibitory activity from LIA (C)), CML-spleen ferritin ([-1), 
and  normal spleen ferritin  (A)  by concanavalin A-Sepharose. Absorbance  is not  shown but was 
found in fractions  1 and 6  for LIA and fractions  1, 2, and 5-10 for the CML and normal spleen 
ferritin. Control colony and cluster numbers ranged from 310 to 450. 
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Fro.  7.  Titration curve of the inhibitory activity of LIA and ferritin. Control colony and duster 
numbers ranged from  110 to 450. The numbers in parentheses designate the number of different 
preparations used. Each sample was assayed on 1-3 different target marrow samples and the curve 
for the CML spleen ferritin and CML spleen ferritin (pH 4.7) was an average of the results of five 
marrows. 17, normal heart; m, normal placental; FII normal liver; O, CML  spleen, O, Hodgkin's 
spleen; ~, normal spleen;/k, CML-spleen (pH 4.7); &, LIA (SDS);  A, LIA (pH 4.7). 
into those samples that responded to the activities and those that did not respond.  In 
1 16 of the  1 18  hone  marrow  samples examined,  the  five  preparations  tested worked 
identically.  Divergence between the preparations was only observed in two cases (data 
not shown). 
Discussion 
Ferritins from mammalian tissue can be resolved into acidic and basic components 
by IEF, and are considered to be families of hybrid molecules consisting of different 
proportions of two subunits,  H  and  L  (15-17,  19-22).  The more acidic  isoferritins 
contain greater proportions of the H  subunits, and the most basic isoferritins appear BROXMEYER, BOGNACKI,  DORNER,  AND  DE  SOUSA  1439 
FIG. 8.  Comparative action of LIA and ferritin on colony- and cluster-forming ceils from patients 
with leukemia. Control colony and cluster numbers from the patients with leukemia ranged from 43 
to 1,010 and numbers from the normal donors ranged from 150 to 380. 
to  be  composed  of homopolymers of L  subunits.  We  have  now  identified  LIA,  a 
suppressor activity of normal granulocyte and macrophage progenitor cells, as acidic 
isoferritins. This defines a functional role for acidic isoferritins in normal and abnormal 
regulation of the production of granulocytes and macrophages, and is the first clear 
demonstration that acidic ferritins can be distinguished from basic ferritins function- 
ally, with regard to a  property different from iron uptake (41). 
The identity of LIA as acidic isoferritins was established by various criteria: (a) The 
inhibitory activity in  preparations  of LIA  and  ferritin copurified with  the  protein 
bands of LIA and ferritin after isolation by nonreducing SDS-PAGE and with acidic 
isoferritins after isolation by IEF. (b) Ferritin was found in LIA samples by Ouchter- 
lony gel diffusion using antisera that recognize acidic isoferritins and H  subunits, and 
90-94% of the total protein of LIA preparations was determined by radioimmunoassay 
to consist  of ferritin.  (c)  Inhibitory activity characteristic of LIA was  found  in  all 
ferritin  preparations  analyzed  and  the  greatest  amount  of activity was  noted  in 
preparations enriched for acidic isoferritins. Basic isoferritins (pH >5.(3)  isolated by 
IEF were inactive as inhibitors. (d) The inhibitory activity present in LIA and ferritin 
preparations, but not in preparations containing NAIA, was inactivated by a battery 
of antisera specific for ferritin, including antisera relatively specific for acidic isofer- 
ritins.  (e)  The  inhibitory activity in  LIA  and  ferritin had  similar  physicochemical 
characteristics. The inactivation by periodate treatment and the binding to concan- 
avalin  A-Sepharose and  elution by a-methyl  mannose  is  also  consistent  with  LIA 
being an acidic isoferritin because the acidic, but not the more basic, ferritins bind to 
concanavalin A-Sepharose (42). 
We were not able previously to detect LIA in bone marrow and blood cells from 
normal donors (I-3, 5, 6)  but as shown here, this type of inhibitory activity was also 1440  ACIDIC ISOFERRITINS,  REGULATORS OF  MYELOPOIESIS 
found in heart, spleen, placenta, and liver tissues from normal individuals. This was 
probably due to a combination of factors. Acidic isoferritins are elevated in leukemia 
and lymphoma, but are present in very low concentrations in bone marrow and blood 
cells and in serum from normal donors (16, 17, 19). Crude preparations of cell extracts 
and conditioned medium were used, and it is now apparent that proteolytic enzymes 
inherent  in  these  preparations  can  inactivate  the  inhibi.tory  activity  of  ferritin. 
Additionally, small quantities of inhibitory activity of acidic isoferritins from normal 
cells  may have gone  undetected  because  our  assay  depends  on  the  suppression  of 
colony formation stimulated  by GM-CSF.  We have now been able to detect  acidic 
isoferritin  inhibitory activity in  medium conditioned  by human placental cells and 
adherent mononuclear bone marrow and blood cells from normal donors which also 
contains GM-CSF (H. E. Broxmeyer and J. Bognacki, unpublished observations). The 
stimulatory activity of these crude preparations of conditioned medium are enhanced 
by 50-100% after removal or inactivation of the acidic isoferritins, by preincubation 
of the  conditioned  medium with  antiserum  to acidic  isoferritins,  or by passing the 
conditioned medium over Sepharose 6B columns. Although the GM-CSF-containing 
conditioned medium used in these studies contained acidic ferritin, the sensitivity of 
CFU-CM to suppression by acidic isoferritins is enhanced (e.g., 60 vs. 40% inhibition) 
by using GM-CSF preparations depleted of acidic isoferritins (unpublished observa- 
tions). 
The  inhibitory  activity was  detected  at  concentrations  as  low as  10-17-10 -19  M, 
assuming a  molecular weight  of 550,000.  These results  bring the  potency of acidic 
isoferritins  into  the  range  of activity  noted  from  lactoferrin,  another  iron-binding 
glycoprotein, which at concentrations in the range of 10  -17 M  inhibits the production 
of GM-CSF from monocytes and macrophages. It remains to be determined whether 
the  final  effect  is  due  to  a  direct  action  on  the  colony-forming cell  (CFU-GM),  a 
single molecule, multiple-target hit situation, or due to a cascade of events set off by 
acidic isoferritin molecules. 
It  has been  shown  by others  that  the  highest  iron  content  is  found  in  the  most 
acidic  isoferritins  from human  heart  and  liver,  that  iron  concentrations  in  ferritin 
decrease with rising pI (41, 43), and that the acidic fractions take up iron more rapidly 
than the basic ones (41). However, in contrast to lactoferrin, which must be in an iron 
saturated form to bind to mononuclear phagocytes and to inhibit production of GM- 
CSF  (9,  10),  acidic  isoferritins  do  not  appear  to  require  iron  saturation  for  their 
inhibitory activity. 
The relevance of acidic isoferritins as regulators of myelopoiesis in vivo remains to 
be determined,  but  the low concentrations  needed  for activity in  vitro suggest  that 
they  may be of importance  as  physiological  regulators,  a  role we  have postulated 
previously for lactoferrin (9).  The acidic isoferritins may be steady state regulators of 
the production of granulocytes and macrophages, but the increase of acidic isoferritin 
inhibitory activity during leukemia and lymphoma, and the insensitivity of "leuke- 
mia" colony-forming cells to inhibition  by the acidic isoferritins, also suggest a  role 
for these substances in the progression of leukemia. In this context, it is of interest that 
lactoferrin  inhibitory  activity  is  deficient  or absent  during  leukemia  and  that  this 
deficiency coincides with the presence of increased levels of acidic isoferritin inhibitory 
activity.  This  suggests  that  a  compensatory  feedback  system  is  operating  during 
leukemia. From in vivo studies with mice infected with Abelson or Friend virus and BROXMEYER, BOGNACKI, DORNER, AND DE SOUSA  1441 
from a correlation of in vitro studies with disease progression in man (1-8; and L. Lu 
and  H.  E.  Broxmeyer, unpublished  observations)  it  appears  that  insensitivity  of 
leukemia CFU-GM to inhibition by acidic isoferritins precedes the increase in acidic 
isoferritin inhibitory activity measured against normal CFU-GM. 
Another leukemia-associated inhibitor (LAI) has been reported by others (44, 45). 
LAI has many characteristics in common with LIA, although subtle differences have 
been noted. It remains to be determined whether LAI is also a population of ferritin 
molecules. 
The identification of LIA as acidic isoferritins will make possible the more precise 
definition of its  action  in  vitro and  in  vivo, its  exact  role and  significance in  the 
regulation  of normal  and  abnormal  myelopoiesis, and  the  characterization of the 
mechanisms whereby "leukemia" cells escape its action. 
Summary 
Acidic isoferritins have been identified as leukemia-associated inhibitory activity 
(LIA), which suppresses colony and cluster formation of colony-forming unit-granu- 
locyte macrophages from normal donors but not from patients with leukemia. LIA 
was  detected in all  the ferritin preparations  tested, including ferritin isolated from 
normal heart, spleen,  liver, and  placental  tissues,  and  from the spleens of patients 
with chronic myelogenous leukemia and Hodgkin's disease. Purified preparations of 
LIA were composed almost  entirely of acidic isoferritins, as  determined by immu° 
noassay, radioimmunoassay, and  isoelectric focusing. The inhibitory activity in the 
LIA and ferritin samples was inactivated by a battery of antisera specific for ferritin, 
including  those  prepared  against  acidic  isoferritins  from normal  heart  and  spleen 
tissues from patients with Hodgkin's disease, and those previously absorbed with basic 
isoferritins. Antisera absorbed with acidic isoferritins did not inactivate the inhibitory 
activity. Separation of LIA and  chronic myelogenous leukemia and  normal spleen 
ferritin by sodium dodeeyl sulfate-polyacrylamide gel electrophoresis and isoelectric 
focusing confirmed that the regions of peak inhibitory activity corresponded in each 
to  an  apparent  molecular  weight  of ~550,000  and  to  a  pI  value  of 4.7.  Similar 
physicochemical  characteristics  included  inactivation  by  methods  that  dissociate 
ferritin molecules into subunits and by treatment with trypsin, chymotrypsin, pronase, 
and  periodate. The purified preparations  were extremely stable to heat  treatment. 
The glycoprotein nature of the inhibitory activity was substantiated because it bound 
to concanavalin A-Sepharose and  was eluted off by a-methyl mannose.  Inhibitory 
activity of the acidic isoferritins was detected at concentrations as low as 10-aT-10  -19 
M  and  iron saturation  did not  appear to be necessary for its action. These results 
implicate acidic isoferritins in the regulation of normal myelopoiesis and suggest a 
role for them in the progression of leukemia. 
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